Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
1(50.0%)
N/A
1(50.0%)
2Total
Phase 1(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01971684Completed

ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP

Role: collaborator

NCT01713738Phase 1Completed

Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Role: collaborator

NCT01713855Not ApplicableCompleted

Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura

Role: collaborator

All 3 trials loaded